$1.2 Billion Pact For AI Drug Discovery Signed By Sanofi With Atomwise
A $1.2 billion pact has been signed between Sanofi and Atomwise in an exclusive AI-powered drug discovery deal, starting with $20 million for 5 drug targets.
Created on August 17|Last edited on August 17
Comment
In a massive deal announced today, Sanofi has put $1.2 billion on the table with AI drug discovery company Atomwise to conduct various research and development projects using their AtomNet platform.
This deal starts with a $20 million payment upfront to kickstart the discovery and research of up to five key drug targets which will be exclusive to Sanofi. Payments beyond this will fund additional research and development products and reward other milestones; Tiered royalties for developed products will also be granted to Atomwise.
Atomwise uses AI to conduct their drug discovery efforts, leveraging machine learning models within their AtomNet platform to compute the exact way small molecules and proteins bind. With the endless complexity that defines how these tiny puzzle pieces connect, the use of focused AI models which have learned the physics that allows these microscopic connection to happen is simply required for efficient research.
Find out more
Add a comment
Tags: ML News
Iterate on AI agents and models faster. Try Weights & Biases today.